New PARP On The Block: BioMarin Starts Phase III, Could Prove To Be Best-In-Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Class’s comeback gets more fuel at AACR/NCI/EORTC targeted therapies meeting. Evidence indicates BioMarin may have the most powerful PARP inhibitor, though AstraZeneca and Tesaro are slightly further in development.